Skye's stock sinks fol­low­ing eye dis­ease fail­ure as com­pa­ny shifts fo­cus to obe­si­ty

Skye Bio­science is aban­don­ing its en­tire eye dis­ease pipeline fol­low­ing a Phase 2a tri­al fail­ure, and it’s piv­ot­ing to one of the hottest cat­e­gories in …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.